BRPI0418973A - composições de risedronato e seus métodos de uso - Google Patents

composições de risedronato e seus métodos de uso

Info

Publication number
BRPI0418973A
BRPI0418973A BRPI0418973-6A BRPI0418973A BRPI0418973A BR PI0418973 A BRPI0418973 A BR PI0418973A BR PI0418973 A BRPI0418973 A BR PI0418973A BR PI0418973 A BRPI0418973 A BR PI0418973A
Authority
BR
Brazil
Prior art keywords
risedronate
compositions
methods
polymorph
solvate
Prior art date
Application number
BRPI0418973-6A
Other languages
English (en)
Portuguese (pt)
Inventor
David Ernest Burgio Jr
Pamela Jean Schofield
Maurice Kent Gately
Jun Shi
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34958880&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0418973(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of BRPI0418973A publication Critical patent/BRPI0418973A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0418973-6A 2004-07-23 2004-09-25 composições de risedronato e seus métodos de uso BRPI0418973A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/897,897 US20050070504A1 (en) 2001-12-21 2004-07-23 Risedronate compositions and their methods of use
PCT/US2004/031975 WO2006022755A1 (en) 2004-07-23 2004-09-25 Risedronate compositions and their methods of use

Publications (1)

Publication Number Publication Date
BRPI0418973A true BRPI0418973A (pt) 2007-12-04

Family

ID=34958880

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418973-6A BRPI0418973A (pt) 2004-07-23 2004-09-25 composições de risedronato e seus métodos de uso

Country Status (20)

Country Link
US (1) US20050070504A1 (enExample)
EP (1) EP1776123A1 (enExample)
JP (3) JP5377852B2 (enExample)
KR (2) KR20070038115A (enExample)
CN (1) CN101146542A (enExample)
AR (1) AR046036A1 (enExample)
AU (2) AU2004322703B2 (enExample)
BR (1) BRPI0418973A (enExample)
CA (1) CA2564898A1 (enExample)
IL (1) IL180907A0 (enExample)
IS (1) IS8597A (enExample)
MA (1) MA28778B1 (enExample)
MX (1) MX2007000967A (enExample)
NO (1) NO20071058L (enExample)
NZ (1) NZ552799A (enExample)
PE (1) PE20060144A1 (enExample)
RU (1) RU2007103306A (enExample)
TW (1) TWI351286B (enExample)
WO (1) WO2006022755A1 (enExample)
ZA (1) ZA200701308B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162053A0 (en) * 2001-12-21 2005-11-20 Procter & Gamble Method for the treatment of bone disorders
EP2851105A1 (en) * 2002-05-10 2015-03-25 F. Hoffmann-La Roche AG Bisphosphonic acids for treatment and prevention of osteoporosis
WO2004056373A1 (en) * 2002-12-20 2004-07-08 F. Hoffmann-La Roche Ag High dose ibandronate formulation
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US20080287400A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
AU2011218625B2 (en) * 2004-05-24 2014-03-20 Theramex HQ UK Limited Dosage forms of risedronate
US20080286359A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US7473684B2 (en) 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
ES2567595T3 (es) * 2005-10-12 2016-04-25 Opko Renal, Llc Métodos y artículos para tratar la insuficiencia y la deficiencia de 25-hidroxivitamina D
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
KR100844256B1 (ko) 2007-03-23 2008-07-07 코오롱제약주식회사 리세드로네이트와 비타민 ｄ를 포함하는 대사성 골질환치료용 약제조성물 및 이의 제조방법
JP2011529901A (ja) * 2008-07-31 2011-12-15 味の素株式会社 リセドロネートまたはその塩の低投与量形態
KR101379664B1 (ko) * 2008-09-23 2014-04-02 한림제약(주) 리세드론산 또는 그의 염 및 비타민 ｄ를 포함하는 약학 조성물
KR101102364B1 (ko) 2009-09-18 2012-01-03 한림제약(주) 비스포스포네이트 유도체 및 고용량의 콜레칼시페롤을 포함하는 약학 조성물
PT106978A (pt) * 2013-05-31 2014-12-02 Tecnimede Sociedade Tecnico Medicinal S A Composição sólida oral contendo ácido ibandrónico e vitamina d

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA777769A (en) * 1963-03-18 1968-02-06 H. Roy Clarence Substituted methylene diphosphonic acid compounds and detergent compositions
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
FR2531088B1 (fr) * 1982-07-29 1987-08-28 Sanofi Sa Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
CA1339805C (en) * 1988-01-20 1998-04-07 Yasuo Isomura (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active
GB2217988B (en) * 1988-04-11 1992-04-01 Gould Leonard W Regimen for increasing bone density in humans
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5227506A (en) * 1989-09-06 1993-07-13 Merck & Co., Inc. Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors
NL8902727A (nl) * 1989-11-06 1991-06-03 Philips Nv Objecthouder voor ondersteuning van een object in een geladen deeltjesbundelsysteem.
EP0650361B1 (en) * 1992-06-30 1999-04-28 PROCTER & GAMBLE PHARMACEUTICALS, INC. Compositions for the treatment of arthritis containing phosphonates and nsaids
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
US6008206A (en) * 1994-09-21 1999-12-28 Merck & Co., Inc. Sodium alendronate preparation for local administration
US6750216B2 (en) * 1996-03-08 2004-06-15 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5730715A (en) * 1996-06-14 1998-03-24 Becton Dickinson And Company Method for the iontophoretic administration of bisphosphonates
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
SK284690B6 (sk) * 1997-06-11 2005-09-08 The Procter And Gamble Company Ústna dávkovacia forma na zvýšenie ochrany horného tráviaceho traktu
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) * 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US6331533B1 (en) * 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
US6225801B1 (en) * 1999-01-14 2001-05-01 Lucent Technologies Inc. Article comprising electronic circuits and devices with magnetically programmable electrical resistance
JP2001253827A (ja) * 2000-02-15 2001-09-18 Pfizer Prod Inc 骨粗鬆症を治療するための組成物および方法
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
KR100864743B1 (ko) * 2000-06-20 2008-10-22 노파르티스 아게 비스포스포네이트의 투여 방법
US6593310B1 (en) * 2000-11-21 2003-07-15 Arthropharm Pty. Ltd. Treatment of osteoporosis
WO2003051373A1 (en) * 2001-12-13 2003-06-26 Merck & Co., Inc. Liquid bisphosphonate formulations for bone disorders
EP2851105A1 (en) * 2002-05-10 2015-03-25 F. Hoffmann-La Roche AG Bisphosphonic acids for treatment and prevention of osteoporosis
US20040188316A1 (en) * 2003-03-26 2004-09-30 The Procter & Gamble Company Kit for pharmaceutical use

Also Published As

Publication number Publication date
AR046036A1 (es) 2005-11-23
ZA200701308B (en) 2008-07-30
PE20060144A1 (es) 2006-04-17
CN101146542A (zh) 2008-03-19
AU2004322703B2 (en) 2010-12-02
US20050070504A1 (en) 2005-03-31
JP5910698B2 (ja) 2016-04-27
WO2006022755A1 (en) 2006-03-02
IS8597A (is) 2007-01-24
MX2007000967A (es) 2007-07-11
CA2564898A1 (en) 2006-03-02
AU2004322703A1 (en) 2006-03-02
JP2008507513A (ja) 2008-03-13
TW200603816A (en) 2006-02-01
IL180907A0 (en) 2007-07-04
JP5761274B2 (ja) 2015-08-12
AU2011200905A1 (en) 2011-03-24
KR20080083219A (ko) 2008-09-16
JP2013231087A (ja) 2013-11-14
NZ552799A (en) 2010-04-30
RU2007103306A (ru) 2008-09-10
JP2015038135A (ja) 2015-02-26
KR20070038115A (ko) 2007-04-09
JP5377852B2 (ja) 2013-12-25
NO20071058L (no) 2007-02-22
TWI351286B (en) 2011-11-01
EP1776123A1 (en) 2007-04-25
MA28778B1 (fr) 2007-08-01

Similar Documents

Publication Publication Date Title
BRPI0418973A (pt) composições de risedronato e seus métodos de uso
USRE34656E (en) Use of tetracycline to enhance bone protein synthesis and/or treatment of bone deficiency
HRP20230272T1 (hr) Postupci za liječenje cistične fibroze
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
CO6361928A2 (es) Modulares de aril metil benzoquinazolinona alostericos positivos del receptor m1
BR0316906A (pt) administração do capsaicinoides
BR0008060A (pt) Composições inibidoras de ciclooxigenase-2 tendo rápido inìcio de eficácia terapêutica
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BR9815442A (pt) Liberação terapêutica dirigida de compostos de vitamina d
JP2015038135A5 (enExample)
MX2015017307A (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington.
ATE417615T1 (de) Pharmazeutische zusammenstellungen und zubereitungen zur behandlung von stoffwechselbedingten knochenerkrankungen
BR0316364A (pt) Combinação de terapia do câncer com um composto anticâncer ativado com gst e uma outra terapia anticâncer
BR112012023139A2 (pt) composição farmacêutica para a prevenção ou o tratamento de doença do fígado gordo não alcóolico e o método para a prevenção ou tratamento de doença do fígado gordo não alcóolico usando a mesma.
BR9912179A (pt) Composição neuroprotetora para a prevenção e/ou tratamento de alterações nervosas e do comportamento devido a estados de ansiedade ou depressão
ES2220047T3 (es) Conbinacion de un antagonista selectivo de nmda nr2b y un inhibidor de la cox-2.
BR0313718A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto
BRPI0514735A (pt) derivados de piridino sulfonamida como moduladores do receptor de quimiocina
HUP0202692A2 (hu) Interleukin-5 inhibitor hatású 6-azauracil-származékok, ezeket tartalmazó gyógyszerkészítmények és intermedierjeik
Lucinda et al. Evidences of osteoporosis improvement in Wistar rats treated with Ginkgo biloba extract: a histomorphometric study of mandible and femur
BRPI0507657A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
BRPI0410623A (pt) composto, processo para preparação de um composto, composição farmacêutica, e, utilização de um composto
BR0315659A (pt) Composição farmacêutica oral para administração uma vez ao dia para a liberação controlada de tramadol ou um sal do mesmo
BR0314700A (pt) Derivados que compreendem esteróis e/ou estanóis e classes especìficas de agentes antiinflamatórios e seu uso no tratamento ou prevenção de doença cardiovascular

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: WARNER CHILCOTT COMPANY, LLC (PR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 31/675 , A61P 19/10

Ipc: A61K 31/663 (2006.01), A61K 31/675 (2006.01), A61P

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8 E 13 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B25E Requested change of name of applicant rejected

Owner name: WARNER CHILCOTT COMPANY, LLC (PR)